User login
A study by Columbia University investigators and funded by CurePSP, a nonprofit patient organization, shows promising developments in the treatment of progressive supranuclear palsy (PSP) and related neurodegenerative disorders. The study, conducted by Columbia researcher Natura Myeku, PhD, and associates and published in Nature Medicine, is focused on decreasing levels of toxic proteins associated with neurodegenerative diseases, including Alzheimer’s disease.
A study by Columbia University investigators and funded by CurePSP, a nonprofit patient organization, shows promising developments in the treatment of progressive supranuclear palsy (PSP) and related neurodegenerative disorders. The study, conducted by Columbia researcher Natura Myeku, PhD, and associates and published in Nature Medicine, is focused on decreasing levels of toxic proteins associated with neurodegenerative diseases, including Alzheimer’s disease.
A study by Columbia University investigators and funded by CurePSP, a nonprofit patient organization, shows promising developments in the treatment of progressive supranuclear palsy (PSP) and related neurodegenerative disorders. The study, conducted by Columbia researcher Natura Myeku, PhD, and associates and published in Nature Medicine, is focused on decreasing levels of toxic proteins associated with neurodegenerative diseases, including Alzheimer’s disease.
